Osteolysis is a complex mechanism resulting from an exacerbated activity of osteoclasts associated or not with a dysregulation of osteoblast metabolism leading to bone loss. This bone defect is not compensated by bone apposition or by apposition of bone matrix with poor mechanical quality. Osteolytic process is regulated by mechanical constraints, by polypeptides including cytokines and hormones and by extracellular matrix components such as proteoglycans (PGs) and glycosaminoglycans (GAGs). Several studies
revealed that GAGs may influence osteoclastogenesis, but data are very controversial: some studies showed a repressive effect of GAGs on osteoclastic differentiation whereas others described a stimulatory effect. The controversy also affects osteoblasts which appear sometimes inhibited by polysaccharides and sometimes stimulated by these compounds. Furthermore, long-term treatment with heparin leads to the development of osteoporosis fueling the controversy. After a brief description of the principal osteoclastogenesis assays, the present chapter summarizes the main data published on the effect of PGs/GAGs on bone cells and their functional incidence on osteolysis.
1.!Introduction
Bone metabolism is tightly regulated by a balance between two bone cell types combining catabolic and anabolic activities. Bone catabolism is supported by multinucleated cells specialized in bone resorption and named osteoclasts. Osteoclasts originate from the monocyte lineage and differentiate by the action of membranous, soluble and extracellular matrix compounds (1) . Among these factors, some are required for proliferation of osteoclast mononuclear progenitors such as macrophage-colony stimulating factor (M-CSF) while other factors such as receptor activator of nuclear factor-kB ligand (RANKL) are more specifically implicated in the commitment of these precursors to their fusion and in the formation of multinucleated resorbing osteoclasts (2Ð4). Bone catabolism depends on the ability of the osteoclast to generate an acidic extracellular compartment between itself and the bone surface which is essential for solubilization of the alkaline salts of bone mineral (5) . This acidic pH is also necessary for the digestion of the organic bone matrix by lysosomal enzymes secreted by osteoclasts (6) . According to their ability to solubilize hydroxyapatite crystals and to digest organic matrix, osteoclasts contribute to the orchestration of the phosphocalcic homeostasis together with the second main bone type cells, the osteoblasts. Osteoblasts originate from mesenchymal stem cells and perform anabolic functions consisting in the formation of extracellular matrix composed by 95% type I collagen (7) . Osteoblast activities are not limited to the formation of bone extracellular matrix but also extend to the osteolytic process. While osteoblasts produce and secrete gelatinase activities (8) controlling partly the collagenic matrix, they release more particularly cytokines and growth factors regulating osteoclast differentiation and activation (2, 3, 9) . Among these polypeptides, RANKL/OPG (osteoprotegerin) is the main molecular couple involved in the communication between osteoblasts and osteoclasts (2, 3) . In this system, RANKL expressed by osteoblasts and also by stromal cells binds to its receptor RANK expressed on the surface of osteoclast precursors and consequently activates TRAF6/NFκB signaling pathway leading to the fusion of osteoclast activity and survival (10, 11) . RANK/RANKL interactions are controlled by OPG which is also produced by osteoblasts/stromal cells. OPG acts as a soluble decoy receptor blocking the binding of RANKL to RANK and subsequently the osteoclastogenesis and the osteolytic process (12, 13) . Extracellular matrix components, especially proteoglycans (PGs) and glycosaminoglycans (GAGs) contribute to the bone remodelling and to the maintenance of bone mass (14) . Thus, PGs and GAGs are involved in the organization of collagen fibers (14) . However, the role of GAGs and PGs in bone metabolism is more complex than initially envisaged and this complexity is mainly related to the structure and the localization of these compounds. PGs exhibit numerous locations and more precisely are associated with intracellular compartments, expressed on the cell surface or anchored in the extracellular matrix and basement membrane in almost all tissues in adults (15). The composition of GAGs is very heterogenous and includes linear polymers which are bound to a core protein to form PGs. There is no unifying feature for core protein structures and then PGs display a great diversity of protein forms. Many core proteins have complex modular structures with protein motifs which have similar sequence to those found in other protein families. GAGs are composed of repeated disaccharidic units of hexosamine and hexuronic acid, except for keratan sulfate in which hexuronic acid is replaced by galactose. According to the epimerization and sulfation of hexosamine and uronic acid, several families of GAGs have been described. All together, this diversity of composition explains in part their very complex biological activities in all tissues and that GAGs/PGs functions are not limited to the control of fibrillogenesis.
The aim of the present review is to better define the function of GAGs and PGs in bone remodeling and more specifically in osteolysis.
The first part of the manuscript will describe the main osteoclastogenesis assays currently used. The review will then focus on the role of PGs in the control of physiological and pathological osteolysis regarding the osteoblastic and osteoclastic components. 
2.!In vitro assays of osteoclastogenesis

+
Murine M-CSF (mM-CSF, R&D System, UK) is dissolved in phosphate buffer/0.1%BSA at 25 µg/mL and stored in single use aliquots at −80¡C until use. Final concentration used is 25 ng/mL (dilution in α-MEM supplemented with 10% FCS) Human or murine RANKL (R&D System, UK) is dissolved in phosphate buffer/0.1%BSA at 100 µg/mL and stored in single use aliquots at −80¡C until use. Final concentration used is 100 ng/mL (dilution in α-MEM supplemented with 10% FCS) Leukocyte (TRAP) staining kit n¡387A (Sigma, France)
Cell preparation and osteoclast differentiation CD11b monocytes are purified from murine bone marrow cells, obtained by flushing the bone marrow from femora and tibiae of 4 week-old C57BL6 male mice. Mice are anesthetized using isoflurane and euthanized by cervical dislocation. CD11b cells are magnetically labelled with CD11b Microbeads and positively selected by MACS technology.
CD11b cells are seeded in 24-well plates (500 × 10 cells/well) in phenol red-free α-MEM, containing 10% FCS and 25 ng/mL mM-CSF. This step is absolutely necessary to improve adhesion of osteoclast precursor to the plastic and to stimulate their proliferation.
After 3 days of culture, medium is replaced by fresh medium containing 10% FCS, 25 ng/mL mM-CSF, with 100 ng/mL hRANKL.
Thereafter, complete medium (with cytokines) are changed every 4 days. The formation of osteoclasts occurred between 15 to 21 days of culture and was detected by TRAP staining ( Figure 1B) (21, 22) . Fluorescent osteoclasts can be obtained using similar technique with CD11b isolated from GFP-mice ( Figure 1C ).
Differentiation assay from human CD14 cells Materials and reagents
Human peripheral blood from healthy volunteer donors and collected on EDTA or citrate buffer CD14 microbeads and MACS technology (Miltenyi Biotec, Germany)
Fetal calf serum (FCS) (Perbio, Logan, USA), batch specifically selected for osteoclast differentiation Figure 1D) (21, 22) .
The two main factors involoved in osteoclast differentiation process and survival are: i) M-CSF which modulates cell adhesion, differentiation, fusion, resorbing activity and ii) RANKL which is dedicated to the osteoclast fusion, activation and survival.
Osteoclastogenesis can be observed from 30 ng/mL and mRANKL can replace human RANKL with 2 fold higher concentration. RANKL and M-CSF then represent the canonical pathway of osteoclastogenesis and they can be substituted by other protagonists (23) .
It has been shown that several cytokines can be substituted for RANKL to promote osteoclastogenesis in vitro (TNF-α, IL-11, IL-8) (23) . However, osteoclast differentiation is absolutely dependent on RANKL in vivo as confirmed by RANKL knock-out mice which completely lack TRAP-positive immature and mature multinucleated osteoclasts [24] . In contrast, M-CSF can be replaced in vitro and in vivo by VEGF, HGF, FLt-3 ligand or IL-34 for instance (23, 25) .
Resorption assay The best validation of the osteoclastic phenotype is to assess the ability of differentiated cells to resorb a mineralized matrix in vitro. For this, CD14 cells are cultured on dentine or cortical bone slices (for bovine bone for instance, animal dentine: horse, bovine, etc) in the conditions previously described. At the end of the culture period, osteoclasts are removed by bleach; dentin/bone (27) can be used. Briefly, after formation of osteoclasts as described above, the medium are removed and the cell layer is washed three times with PBS without calcium and magnesium. Six hundred microliters of 0.02% EDTA are added per well (6-well plate) and cells are incubated for 20 min at room temperature. EDTA is then removed from the well and replaced by 600 µl of calcium/magnesium-free PBS. A cell scraper is used to harvest the cells in PBS, and the resulting cell suspension is mixed using a pipette to ensure uniform cell dispersal. Two hundred and fifty microliters of this cell suspension is then added to each well (24-well plate) on a dentin slice in 250 µl αMEM, 10% FCS. Cells are allowed to sediment for 20 min at 37¡C before dentin/bone slices are washed. Cells are incubated in 500 µl αMEM, 10% FCS in the presence or the absence of tested compounds/drugs. After incubation, resorption surfaces are assessed as described above ( Figure 1E ) (28) . Resorption lacunae and resorbed surface area can be also revealed and measured by scanning electron microscopy (29, 30) .
In all models described, the main markers used to determine the presence of osteoclasts are TRAP, calcitonin receptor, vitronectin receptor, cathepsin K, and the capacity for resorbing mineralized matrix. In all models, RANKL-induced osteoclastogenesis is specifically inhibited by addition of recombinant OPG or RANK-Fc (4).
3.!Functional activities of PGs and GAGs on osteoclasts
Numerous growth factors/cytokines/receptors carry a heparin binding domain and consequently can bind to isolated GAGs or GAGs from PGs. Thus, GAGs have many biological activities by holding various extracellular molecules which play key roles in bone metabolism and in bone remodelling. Indirect evidence of the role of GAGs in bone remodelling has been published by Kram et al (31) .
These authors have shown that heparanase, a heparin sulfate-degrading endoglycosidase, is weakly expressed throughout the bone marrow with a substantial increase in osteoblasts and osteocytes and in contrast heparanase is absent from osteoclasts. Interestingly, Shinmyouzu et al (33) published that dermatan sulfate inhibits osteoclast formation by binding to RANKL. However, these authors used non-relevant physiological concentrations of dermatan sulfate (300 µg/ml) and non-purified osteoclast precursors to study osteoclastogenesis. To continue in the controversial data, Ariyoshi et al (32) observed that hyaluronic acid increases osteoclastogenesis through activation of CD44 signaling pathway whereas Chang et al (38) demonstrated opposite activities and showed an activation of TLR4 signaling pathway without any involvement of CD44. Finally, using fully differentiated osteoclasts derived from human peripheral blood monocytes, Pivetta et al (39) revealed that hyaluronan inhibits their migration on collagen as well as their ability to resorb bone matrix. These effects are mainly due to a decrease of TRAP, MMP-9 and cathepsin K activities and to the increased levels of TIMP-1. The role of CD44 was confirmed by using blocking anti-CD44 antibodies which fully abrogated hyaluronan effects.
Hyaluronan then hampers osteoclast migration through its activity on CD44 (40) . Overall, the data published show that GAGs inhibit osteoclastogenesis and their resorption activity by inhibiting the adhesion and fusion of osteoclast precursors. These activities appear independent of RANKL signaling pathway but may involve CD44 and TLR4 depending on the GAGs used.
In contrast to RANKL, OPG has a heparin binding domain. OPG belongs to the family of the TNF receptor family and contains three structural domains specifically influencing its biological activities. The first one is a cysteine-rich domain in the N-terminal position which is essential for the inhibition of osteoclastogenesis as well as for the dimerization of OPG via the Cys400. The second domain + + corresponds to two death domain homologous regions. The third domain is a heparin-binding domain which is able to interact with numerous proteoglycans (41) . Full length OPG binds to GAGs with a high affinity (Kd: 0.28 nM for heparin) in contrast to OPG-Fc in which the heparin-binding domain is lacking (36, 37) . Therefore, the first role of the OPG heparin-binding domain has been revealed by Standal et al (42) who demonstrated that myeloma cells internalize and degrade OPG through its binding to syndecan-1 and consequently induce osteolysis in patients. Thus, PGs control the bioavailability of OPG one of the main inhibitor of osteoclastogenesis and bone resorption. PGs are involved in OPG-induced chemotaxis of monocytes (43) . Indeed, OPG can interact with syndecan-1 expressed by monocytes (potential osteoclast precursors) and can stimulate the cell migration. In this context, OPG is a chemotactic factor for monocytes which can be recruited in inflammatory context or during osteolysis process. In light of these studies, PGs and GAGs exert a very complex pattern of activities which are not arguable if the biological context is taken into account (inhibition of osteoclastogenesis in vitro, bioavailability of OPG and monocyte chemotaxis in favour of pro-osteolytic activity).
4.!Functional activities of PGs and GAGs on osteoblasts
Bone remodelling is a balance between osteoblast and osteoclast activation and the functional activity of the first is influenced by the other one. In this context, similarly to their activities on osteoclasts, PGs and GAGs strongly modulate osteoblast metabolism (14, 44) .
In bone microenvironment, membrane or soluble forms of RANKL are mainly expressed by stromal cells and osteoblasts which control osteoclastogenesis by this pathway (2, 4) . OPG regulates the half-life of membrane RANKL and GAGs inhibit the OPG-induced shortened half-life of RANKL (36) . In this specific context, GAGs may increase the half-life of RANKL by inhibiting OPG activity and thus act as a pro-osteoclastic factor. Furthermore, RANKL significantly reduces ERK activity, a putative suppressor of osteoclastogenesis but unfractionated osteoblast-derived GAGs abolish the inhibitory effects of RANKL on ERK activity (35) underlining the fact that osteoblast microenvironment is a potent source of GAGs that promote bone anabolic activities. Although the exact mechanism by which GAGs regulate RANKL activity remains unclear, Cao et al (45) showed that hyaluronan increases RANKL expression in bone marrow stromal cells through CD44 which in turn could stimulate osteoclast activity.
GAGs can be considered as polysaccharides containing protein-binding domains that coordinate mesenchymal stem cell commitment and growth, and ultimately, osteoblast phenotype (44) . Among the heparan sulfate-binding factors known to be essential in to this (50) . These authors demonstrated that MC3T3-E1 cells under osteogenic conditions decrease their chondroitin and dermatan sulfate PGs (biglycan, decorin, and versican) but increase glypican-3. This shift in expressed HSPGs is concomitant to the switch of FGR1 to FGR3 expression related to the commitment to osteoblast differentiation (51) . Similarly to FGF, TGFs stored into the bone matrix could be released during bone resorption and modulate in turn osteoblast and ostoclast metabolism (52). Bi et al (53) revealed that the absence of the critical TGFβ-binding proteoglycans, biglycan and decorin, prevents TGFβ from proper sequestration within the extracellular matrix. Thus proteoglycans appear essential for maintaining an appropriate number of osteoblasts and osteoclasts by modulating their proliferation and/or differentiation. More recently, Bi et al revealed that biglycan deficiency upmodulates osteoclast differentiation and activation due to defective osteoblasts but independently of RANKL and OPG production (53) . The effects of GAGs on osteoblast lineage are dependent on their sulfation. Indeed, sulfation strongly enhances the biological activity of BMPs (TGF member family) by continuously binding the ligands to their receptors and by enhancing osteoblast differentiation (54) . In agreement with these data, desulfation of GAGs expressed by MG63 cells delayed in vitro mineralization process (55) . Overall, these data point out the key role of GAGs in bone formation and their ability to modulate osteoblast differentiation by indirect mechanism and more specifically by controlling bone cytokines/growth factors. It is also important to keep in mind, that osteolysis is the result of both osteoblast and osteoclast activity and even if osteoblasts are bone cells specialized in bone formation they contributes in part to the degradation of osseous organic matrix.
5.!PGs/GAGs and bone remodelling: a complex dysregulation of the anabolic/catabolic balance
It is well known that long-term administration of heparin was shown to lead to the development of osteoporosis (56Ð58). Thus, rats treated once daily by subcutaneous injections of heparin exhibited decreased trabecular bone volume both by decreasing the rate of bone formation and increasing the rate of bone resorption. Barbour et al (59) also showed that 36% of pregnant women undergoing long-term heparin treatment had a 10% reduction in femoral bone mineral density. However, the mechanism sustaining this osteoporosis was unclear and it was difficult to determine if the effects on bone resorption were due to the direct effect of heparin on osteoclasts or indirectly via its osteoblast activity. Furthermore, these controversial findings on GAG effects on osteoclastogenesis are intensified by the study of Folwarczna et al (60) who showed that in a rat model, low concentrations of heparin increased the formation of osteoclasts, whereas it decreased with the highest concentrations. In mouse bone marrow cell cultures, heparin suppressed the formation of osteoclasts, with the exception of low concentrations of standard heparin which intensified this process (60) . In fact, heparin activity on bone remodelling probably results from a more complex mechanisms altering simultaneously osteoclast and osteoblast metabolisms.
Heparin may increase the resorption process through the release of pro-resorptive factor by osteoblast/stromal cells (62) explaining in part the discrepancy between the in vivo and in vitro results and heparin may also exert an inhibitory activity on bone formation by decreasing osteoblast number and by inhibiting the mineralization process (56Ð58, 61).
6.!Conclusions
GAGs and PGs exert a broad panel of action targeting simultaneously osteoblasts and osteoclasts. Unfortunately long-term administration of heparin leads to the development of osteoporosis. In this context, although the mechanisms of action of lowmolecular-weight heparins are not yet totally elucidated their use is preferred to unfractionated heparin (61) . More specifically, the effect of low-molecular-weight heparins on osteoblasts and on osteoblastÐosteoclast communications needs to be investigated and complementary studies to determine whether the effects of heparin on bone are reversible are needed. 
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